Busse Jason W, Douglas Joyce, Chauhan Tara S, Kobeissi Bilal, Blackmer Jeff
Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada.
Pain Res Manag. 2020 Feb 17;2020:8380171. doi: 10.1155/2020/8380171. eCollection 2020.
Physician adherence to guideline recommendations for the use of opioids to manage chronic pain is often limited.
In February 2018, we administered a 28-item online survey to explore perceptions of the 2017 Canadian guideline for opioid therapy and chronic noncancer pain and if physicians had altered practices in response to recommendations.
We invited 34,322 Canadian physicians to complete our survey, and 1,128 responded for a response rate of 3%; 687 respondents indicated they prescribed opioids for noncancer pain and answered survey questions about the guideline and their practice. Almost all were aware of the guideline, 94% had read the document, and 89% endorsed the clarity as good or excellent. The majority (86%) felt the guideline was feasible to implement, but 66% highlighted resistance by patients, and 63% the lack of access to effective nonopioid treatment as barriers. Thirty-six percent of respondents mistakenly believed the guideline recommended mandatory tapering for patients using high-dose opioid therapy (≥90 mg morphine equivalent per day), and 58% felt they would benefit from support for opioid tapering. Seventy percent of respondents had changed practices to align with guideline recommendations, with 51% engaging some high-dose patients in opioid tapering and 43% reducing the number of new opioid starts.
There was high awareness of the 2017 Canadian opioid guideline among respondents, and preliminary evidence that recommendations have changed practice to better align with the evidence. Ongoing education is required to avoid the misunderstanding that opioid tapering is mandatory, and research to identify effective strategies to manage chronic noncancer pain is urgently needed.
医生对使用阿片类药物治疗慢性疼痛的指南建议的遵循程度往往有限。
2018年2月,我们进行了一项包含28个项目的在线调查,以探讨对2017年加拿大阿片类药物治疗与慢性非癌性疼痛指南的看法,以及医生是否因这些建议而改变了治疗方式。
我们邀请了34322名加拿大医生完成我们的调查,1128人做出回应,回应率为3%;687名受访者表示他们为非癌性疼痛开具阿片类药物,并回答了有关该指南及其治疗方式的调查问题。几乎所有人都知晓该指南,94%的人阅读过该文件,89%的人认为其清晰度良好或极佳。大多数人(86%)认为该指南可行,但66%的人强调患者的抵触情绪,63%的人指出缺乏有效的非阿片类治疗方法是障碍。36%的受访者错误地认为该指南建议对使用高剂量阿片类药物治疗(每天≥90毫克吗啡当量)的患者进行强制性减量,58%的人认为他们将从阿片类药物减量支持中受益。70%的受访者已改变治疗方式以符合指南建议,51%的人让一些高剂量患者参与阿片类药物减量,43%的人减少了新的阿片类药物处方数量。
受访者对2017年加拿大阿片类药物指南的知晓度很高,初步证据表明这些建议已改变了治疗方式,使其更好地与证据相符。需要持续开展教育以避免误解阿片类药物减量是强制性的,并且迫切需要开展研究以确定管理慢性非癌性疼痛的有效策略。